Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 17/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159385 | 1.00 | ERBB2 (0.55) | ERBB2KMT2AAHR | |
| SCHEMBL4056632 | 0.86 | ERBB2 (0.56) | ERBB2KMT2AAHR | |
| SCHEMBL4056631 | 0.86 | ERBB2 (0.56) | ERBB2KMT2AAHR | |
| SCHEMBL5761839 | 0.84 | ERBB2 (0.53) | ERBB2KMT2A | |
| SCHEMBL5761845 | 0.84 | ERBB2 (0.53) | ERBB2KMT2A | |
| SCHEMBL22397909 | 0.83 | ERBB2 (0.46) | ERBB2 | |
| SCHEMBL22397906 | 0.83 | ERBB2 (0.46) | ERBB2 | |
| SCHEMBL3075346 | 0.81 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL3075344 | 0.81 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL4154806 | 0.77 | ERBB2 (0.49) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | JENNI WOLFGANG | 2009-04-09 | — | — | US | disclosed |
| EP-1934210-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039226-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | CYP3A5, CYP3A7, CYP3A43 | ERBB2 1997/4885KMT2A 2812/4885AHR 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.